Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

rando321456 Aug. 3 at 11:35 PM

$RGNX $RCKT Fantastic news on the safety data today for the danon therapy, if we're lucky this can get approved in late 2027 or early 2028. It'll be very very interesting if Rocket's patient pop estimate is accurate, if it is this is easily a 2-3 billion dollar therapy(that Regenx gets 10% of for 10 years).

1 · Reply

rando321456 Aug. 3 at 10:25 PM

$RGNX Should be upping the 12 month functional data from 9 patients to 15-20 here pretty soon

0 · Reply

SQUEAKSBANDIT Aug. 3 at 5:29 PM

$RGNX any possible negatives that could drop thurs ?

1 · Reply

Wolfman5960 Aug. 3 at 4:22 PM

$RGNX Looks like Q2 earnings and conference call at 8:00AM ET this Thursday, August 6th: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-host-conference-call-august-6-discuss-second-quarter-0

1 · Reply

BioRich Aug. 3 at 4:22 AM

$SLS For those that didn't see what @ExitLiquidity was referring to, here's my Top 5 Bio Roster Spots for the month of August: 1) $RGNX 2) $KYTX 3) MLTX 4) $UNCY 5) $BIOA Who do you have?

4 · Reply

BioRich Aug. 3 at 3:04 AM

$XBI Who are your Top 5 Bio Roster Spots for the month of August? List them in the comments (or make your own post) so we can have ST reference SP. This is obviously for fun, but also a great way to share ideas. I'll take: 1) $RGNX 2) $KYTX 3) $MLTX 4) UNCY (Not cash tagged because we're only allowed 5 tags per post) 5) $BIOA GUTS is still my #1 Bio in my Portfolio, but most know that so I didn't add it to the list. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

SQUEAKSBANDIT Aug. 1 at 11:05 PM

$RGNX i may have missed it did anyone see who bought the prefunds from the financing? looked like 10MM worth

0 · Reply

Merlintrader Aug. 1 at 9:06 PM

REGENXBIO ($RGNX): Three Late-Stage Programs, a Fully Exercised Financing and a Q3 Regulatory Execution Test https://www.merlintrader.com/regenxbio-stock-hub/

0 · Reply

dcrown Jul. 31 at 10:44 PM

$RGNX hints : https://allsci.com/news/funding/public-equity-offerings/regenxbio-raises-usd-100m-amid-pivotal-year-for-gene-therapy-pipeline/

0 · Reply

Quantumup Jul. 31 at 2:48 PM

BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20

0 · Reply

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

2026-07-19T15:45:15.000Z - 16 days ago

Regenxbio presents long-term data for surabgene lomparvovec

Jul 18, 2026, 2:55 PM EDT - 16 days ago

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

2026-07-17T11:05:39.000Z - 18 days ago

Regenxbio 10M share Spot Secondary priced at $9.00

Jul 17, 2026, 7:00 AM EDT - 18 days ago

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

2026-07-16T20:30:11.000Z - 18 days ago

Regenxbio announces $100M common stock offering

Jul 16, 2026, 4:26 PM EDT - 18 days ago

REGENXBIO Announces Proposed Public Offering of Common Stock

2026-06-29T11:20:21.000Z - 5 weeks ago

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

ABBV

Jun 29, 2026, 7:05 AM EDT - 5 weeks ago

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

2026-06-24T11:10:54.000Z - 5 weeks ago

Regenxbio completes dosing in confirmatory study of RGX-202

Jun 24, 2026, 7:05 AM EDT - 5 weeks ago

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

2026-06-23T10:44:38.000Z - 6 weeks ago

Regenxbio price target raised to $32 from $27 at Baird

2026-06-22T13:58:16.000Z - 6 weeks ago

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

2026-06-22T11:41:10.000Z - 6 weeks ago

Regenxbio aligns with FDA on path forward for Navsunli

Jun 22, 2026, 7:30 AM EDT - 6 weeks ago

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

Jun 22, 2026, 7:01 AM EDT - 6 weeks ago

FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

2026-06-22T10:51:25.000Z - 6 weeks ago

Regenxbio up 25% after saying FDA will reverse rejection, consider application

2026-06-22T10:39:19.000Z - 6 weeks ago

Regenxbio tells WSJ that FDA will reverse rejection of drug

QURE REPL

Jun 22, 2026, 6:30 AM EDT - 6 weeks ago

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

2026-06-05T16:15:27.000Z - 2 months ago

Regenxbio price target lowered to $26 from $30 at H.C. Wainwright

May 20, 2026, 9:30 AM EDT - 2 months ago

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 18, 2026, 4:05 PM EDT - 2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

2026-05-15T15:49:06.000Z - 2 months ago

Regenxbio price target lowered to $16 from $17 at Morgan Stanley

2026-05-15T10:40:05.000Z - 2 months ago

Regenxbio price target lowered to $14 from $25 at BofA

2026-05-15T09:10:09.000Z - 2 months ago

Regenxbio price target lowered to $12 from $37 at Barclays

May 14, 2026, 9:30 AM EDT - 2 months ago

REGENXBIO Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 2 months ago

REGENXBIO Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Transcript: Study result

May 14, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Press release: Study result

May 14, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Slides: Study result

May 14, 2026, 7:10 AM EDT - 2 months ago

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

May 14, 2026, 7:04 AM EDT - 2 months ago

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026, 7:00 AM EDT - 2 months ago

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

May 7, 2026, 7:05 AM EDT - 3 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 6, 2026, 7:05 AM EDT - 3 months ago

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

Apr 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Proxy statement: Proxy filing

Mar 26, 2026, 9:00 AM EDT - 4 months ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

Mar 11, 2026, 12:00 PM EDT - 5 months ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

Mar 11, 2026, 11:45 AM EDT - 5 months ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 10, 2026, 1:30 PM EDT - 5 months ago

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 9:20 AM EDT - 5 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 11:33 AM EST - 5 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

Mar 5, 2026, 2:25 PM EST - 5 months ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

Mar 5, 2026, 8:00 AM EST - 5 months ago

REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

REGENXBIO Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 5 months ago

REGENXBIO Earnings release: Q4 2025

Mar 5, 2026, 7:05 AM EST - 5 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 4, 2026, 7:05 AM EST - 5 months ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 2, 2026, 5:58 PM EST - 5 months ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Feb 25, 2026, 7:05 AM EST - 5 months ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 9, 2026, 4:13 PM EST - 6 months ago

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:05 PM EST - 6 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Jan 29, 2026, 6:06 PM EST - 6 months ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 28, 2026, 7:46 AM EST - 6 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:30 AM EST - 6 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 14, 2026, 1:30 PM EST - 7 months ago

REGENXBIO Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 3:00 PM EST - 7 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Jan 10, 2026, 7:00 AM EST - 7 months ago

REGENXBIO Slides: Corporate presentation

Dec 18, 2025, 7:05 AM EST - 8 months ago

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 8:30 AM EST - 8 months ago

REGENXBIO Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 8 months ago

REGENXBIO Registration statement: Registration Filing

Nov 25, 2025, 7:05 AM EST - 9 months ago

REGENXBIO to Participate in Upcoming Investor Conference

Nov 11, 2025, 1:20 PM EST - 9 months ago

REGENXBIO Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 9 months ago

REGENXBIO Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 9 months ago

REGENXBIO Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

REGENXBIO Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

REGENXBIO Earnings release: Q3 2025

Nov 6, 2025, 7:05 AM EST - 9 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Oct 30, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 29, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

rando321456 Aug. 3 at 11:35 PM

1 · Reply

rando321456 Aug. 3 at 10:25 PM

$RGNX Should be upping the 12 month functional data from 9 patients to 15-20 here pretty soon

0 · Reply

SQUEAKSBANDIT Aug. 3 at 5:29 PM

$RGNX any possible negatives that could drop thurs ?

1 · Reply

Wolfman5960 Aug. 3 at 4:22 PM

1 · Reply

BioRich Aug. 3 at 4:22 AM

$SLS For those that didn't see what @ExitLiquidity was referring to, here's my Top 5 Bio Roster Spots for the month of August: 1) $RGNX 2) $KYTX 3) MLTX 4) $UNCY 5) $BIOA Who do you have?

4 · Reply

BioRich Aug. 3 at 3:04 AM

0 · Reply

SQUEAKSBANDIT Aug. 1 at 11:05 PM

$RGNX i may have missed it did anyone see who bought the prefunds from the financing? looked like 10MM worth

0 · Reply

Merlintrader Aug. 1 at 9:06 PM

REGENXBIO ($RGNX): Three Late-Stage Programs, a Fully Exercised Financing and a Q3 Regulatory Execution Test https://www.merlintrader.com/regenxbio-stock-hub/

0 · Reply

dcrown Jul. 31 at 10:44 PM

$RGNX hints : https://allsci.com/news/funding/public-equity-offerings/regenxbio-raises-usd-100m-amid-pivotal-year-for-gene-therapy-pipeline/

0 · Reply

Quantumup Jul. 31 at 2:48 PM

0 · Reply

Dont_believe_pumper Jul. 31 at 12:00 PM

$RGNX this company rarely uses its PR team . Looks like Pr team is ever sleeping for them …

0 · Reply

dcrown Jul. 30 at 7:27 PM

$RGNX who is selling , geez

0 · Reply

maphere Jul. 30 at 7:01 PM

$RGNX $ABBV Place your bets whether Abbvie finally discusses the 314 program tomorrow. Big reveal EOY which could move into a BLA 1Q27 for a global wAMD program...and as suggested before, are they going for SOC which is a big jump to getting a small percentage due to the SR delivery to this is better than SOC treatment. Does RGNX PR their ER tomorrow as well and hint towards FDA nod on 121? Nice to have 3 solid catalysts, 2 of which are substantial indications that could propel this stock much higher.

1 · Reply

SQUEAKSBANDIT Jul. 30 at 2:22 AM

$RGNX anyone considering taking some CAPR tomorrow? anyone considering taking some CAPR tomorrow? if so at what price ?

2 · Reply

Ml55totoag Jul. 29 at 2:59 PM

$RGNX wish me luck people. I loaded my capr train yesterday.

4 · Reply

Ml55totoag Jul. 29 at 2:36 PM

$RGNX capr is exposing corrupt fda. Thank you Linda. FDA will have second thoughts to screw us.

1 · Reply

XQuise Jul. 29 at 11:47 AM

$RGNX 🤝🔙

0 · Reply

BenTheDo Jul. 28 at 3:58 PM

$RGNX I wish this company had better PR. They never tell us when anything is going to happen. Does anyone know when we will hear about the resubmission and/or P3 data?

1 · Reply

rando321456 Jul. 28 at 12:28 PM

$RGNX In light of all the drama around these resubmissions I do think a key caveat for us is that Denali has already received approval in the same indication with similar data, Ultragenyx will also probably be approved in MPSIII with a similar trial in 2 months. Ontop of that the language between Replimune's and Regenx's comms are notably different with no mention of label negotiations out of Replimune.(a little reaching I know) The pathways also seem different with repl just resubmiting and it not being tied to any formal dispute mechanism. I do think we should probably be weighting a longer review cycle as more likely though, especially in the context of Regenx's raise.

3 · Reply

rando321456 Jul. 28 at 2:25 AM

$RGNX Reminder for 202 from Curran: "I think number one, the fact that the protocol was prospectively reviewed by FDA. We received comments on the design of the study and the stats plan around comparison to external controls so we feel like we have -- and none of that change. We haven't altered the pivotal protocol through execution."

0 · Reply

BRITLS Jul. 27 at 8:03 PM

$RGNX well that faded quick

0 · Reply

jancula Jul. 27 at 3:13 PM

$CAPR It's over. $SRPT and $RGNX should be up big way

1 · Reply

Market Cap	500.95M
Revenue (ttm)	170.44M
Net Income (ttm)	-193.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-113.75%
Debt to Equity Ratio	0.00

Volume	447,325
Avg Vol	2,185,082
Day's Range	N/A - N/A
Shares Out	51.70M
Stochastic %K	59%
Beta	0.90
Analysts	Strong Sell
Price Target	$24.27